Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- HEK-293 TNFSF-13B TNFSF-13-B TNFSF13-B IFN? IL10 IFN? CD-40 BAFFR BR-3 IgG-1 TALL1 20 ZTNF-4
- Product Overview:
B lymphocyte stimulator (BLyS), also known as B cell-activating factor (BAFF), is a cytokine that belongs to the TNF ligand superfamily and has roles in B cell survival and differentiation.{52823,52824} It is a type II transmembrane protein with an extracellular C-terminal TNF homology domain that is cleaved from the cell surface by a furin protease and corresponds to the soluble form of BLyS, which circulates as a trimer.{52823,52824,52826} BLyS is encoded by the TNFSF13B gene in humans, expressed primarily in monocytes, macrophages, dendritic cells, and neutrophils, and can be upregulated by IFN-?, IL-10, IFN-?, and CD40 ligand. {52823,52824,52825} Binding of BLyS to the B cell receptors TACI, BCMA, and BAFF-R/BR3 inhibits apoptosis in, as well as increases survival and promotes differentiation of, B cells.{52823,52824} Elevated serum levels of BLyS have been found in patients with rheumatoid arthritis, systemic lupus erythematosus (SLE), and primary Sjögren’s syndrome.{52826} Formulations containing a monoclonal antibody against soluble BLyS have been used in the treatment of SLE.{52827} Cayman’s Soluble BLyS/BAFF (human, recombinant) protein can be used for cell-based assay and ELISA applications. This protein is a disulfide-linked homodimer. The reduced monomer, comprised of BLyS/BAFF (amino acids 134-285) fused to human IgG1 Fc at its N-terminus, consists of 389 amino acids and has a calculated molecular weight of 43.7 kDa. As a result of glycosylation, the monomer migrates at approximately 48-55 kDa by SDS-PAGE under reducing conditions.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.